President Joe Biden’s budget proposal for fiscal 2025 includes a proposal that would allow pharmacy substitution of biosimilar drugs for the reference product, even if they are not designated as ...
The first biosimilars of AstraZeneca/Alexion's blockbuster complement C5 inhibitor Soliris have been launched in the US at a discount to the brand. Both Amgen's Bkemv and Teva/Samsung Bioepis' Epysqli ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results